Skip to main content
LONA
NASDAQ Life Sciences

LeonaBio Flags Going Concern as Cash Dwindles to $51M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$7.965
Mkt Cap
$74.819M
52W Low
$3.6
52W High
$41.3
52W Position info
121% above low
Off High info
81% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

LONA has more than doubled off its 52-week low of $3.6 on light trading volume (0.3× avg).

Summary

LeonaBio's Q2 10-Q discloses a going concern warning, with $51.1M in cash that may not last 12 months, while the Phase 3 ELAINE-3 trial continues to burn cash.


Key Events · Earnings and Guidance · LONA

  • Going Concern Warning

    Management states that its $51.1 million in cash, cash equivalents, and investments at June 30, 2026 may not be sufficient to fund operations through the next 12 months, raising substantial doubt about the company's ability to continue as a going concern.

  • Cash Burn Accelerates

    Net loss for H1 2026 was $52.0 million, up 223% from $16.1 million in H1 2025. Cash used in operations was $37.9 million for the six months, driven by a 201% increase in R&D spending to $24.0 million.

  • Potential Warrant Proceeds

    Series A Common Warrants, exercisable after October 31, 2026, could provide $146.2 million in additional capital if exercised in full. However, exercise is not guaranteed and depends on stock price and investor appetite.

  • ATM Facility Blocked

    The company's $75 million at-the-market equity offering facility with Cantor Fitzgerald and BTIG is currently unusable due to S-3 ineligibility through December 2026, limiting near-term financing options.


Analysis · LONA · Life Sciences

LeonaBio's Q2 10-Q reveals that its $51.1 million in cash and investments may not fund operations through the next 12 months, raising substantial doubt about its ability to continue as a going concern. The company is burning cash rapidly, with a net loss of $52.0 million for the first half of 2026, driven by a 201% increase in R&D spending to $24.0 million as it advances the Phase 3 ELAINE-3 trial for lasofoxifene. While the company has potential capital sources—Series A warrants exercisable after October 31, 2026 could bring in $146.2 million if fully exercised, and an ATM facility exists—the ATM is currently unusable due to S-3 ineligibility through December 2026. The going concern disclosure is a critical red flag that could pressure the stock as investors reassess the company's ability to fund its pivotal trial through topline data expected in the second half of 2027.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LONA was trading at $7.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $74.8M. The 52-week trading range was $3.60 to $41.30. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LONA - Latest Insights

LONA
Nov 16, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.23
Real-time Price: $2.01 info
Change: -$1.22 (-38%) info
Market Cap: $26.414M info
LONA
Nov 16, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.23
Real-time Price: $2.01 info
Change: -$1.22 (-38%) info
Market Cap: $26.414M info
LONA
Sep 22, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.05
Real-time Price: $2.01 info
Change: -$4.04 (-67%) info
Market Cap: $26.414M info
LONA
Aug 31, 2026, 4:31 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $7.92
Real-time Price: $2.01 info
Change: -$5.91 (-75%) info
Market Cap: $26.414M info
LONA
Aug 26, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.01
Real-time Price: $2.01 info
Change: -$6.00 (-75%) info
Market Cap: $26.414M info